IMS Annual Meeting - International Myeloma Society Annual Meeting

Expert shares the evolving role of pharmacy in patient care, emphasizing treatment accessibility and monitoring.

New IMWG/IMS guidelines enhance risk assessment for multiple myeloma, revealing daratumumab's impact on patient outcomes in real-world settings.

New research links rapid CAR T-cell expansion to delayed neurotoxicity in patients with multiple myeloma.

Claudio Cerchione, MD, PhD, discusses the benefits of anti-CD38 quadruplet regimens for older patients with multiple myeloma.

Expert shares the promising potential of Limboseltamab in treating high-risk smoldering multiple myeloma.

Expert shares the latest advancements in CAR T therapy and novel treatments for myeloma, addressing access challenges and promising new options.

Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.

Expert discusses groundbreaking studies on the on-body injector for isatuximab, highlighting its efficacy, safety, and patient convenience.

Pharmacists enhance patient care in multiple myeloma by focusing on infection prevention, CRS management, and optimizing outcomes with T-cell engagers post-CAR T.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Idecabtagene vicleucel shows a lower infection risk than other BCMA therapies for multiple myeloma.

Costimulatory bispecific antibodies revolutionize multiple myeloma treatment, offering deeper responses and flexible sequencing strategies for patients.

New findings reveal that combining daratumumab with lenalidomide significantly enhances MRD negativity and progression-free survival in multiple myeloma maintenance therapy.

Linvoseltamab combined with carfilzomib shows promising results in treating relapsed refractory multiple myeloma.

Iberdomide enhances chimeric antigen receptor (CAR) T-cell therapy effectiveness in multiple myeloma, boosting immune response and cell functionality.

Experts discuss the potential of linvoseltamab in treating high-risk smoldering multiple myeloma, highlighting promising early trial results and response rates.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

Outpatient use of bispecifics and CAR T-cell therapies in multiple myeloma can expand access.

Teclistamab shows promising results in frontline multiple myeloma treatment, achieving high MRD negativity rates, but safety concerns remain.

Teclistamab and other bispecific antibodies enhance multiple myeloma treatment but significantly increase infection risks, necessitating proactive management strategies.

Teclistamab shows promising results in newly diagnosed multiple myeloma, enhancing tolerability and achieving high rates of minimal residual disease negativity.

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

An expert discusses the benefits of anti-CD38 quadruplet regimens for elderly multiple myeloma patients.

An expert discusses CAR T therapy's potential in treating relapsed multiple myeloma, highlighting long-term remissions and access challenges.

An expert discusses the promising results of elranatamab as a consolidative therapy for relapsed/refractory multiple myeloma, enhancing patient outcomes.

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards.

The benefits of the daratumumab-based regimen were seen in all patients, including those with high and standard cytogenic risk levels.

Small molecule agents continue to be beneficial additions to multiple myeloma treatment, even with the development of T-cell redirected therapies.

These interim trial results support the ongoing phase 3 ITHACA trial.